<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837290</url>
  </required_header>
  <id_info>
    <org_study_id>KA12/166</org_study_id>
    <nct_id>NCT01837290</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery</brief_title>
  <official_title>The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Geriatric patients (age ≥ 65 years) undergo surgery for hip fractures that develops due to&#xD;
      osteoporosis and falls. Dialysis-dependent chronic kidney disease is associated with an&#xD;
      increased risk of cardiovascular comorbidity. Elective or urgent surgical operations may be&#xD;
      required for geriatric patients with end stage renal disease. These patients have severe&#xD;
      comorbidities, fluid, electrolyte disturbances and drug metabolism abnormalities during the&#xD;
      perioperative period. For this reasons a careful anesthesia plan should be planned and&#xD;
      performed. Spinal anesthesia can be used for hip fracture surgery at geriatric patients with&#xD;
      chronic renal failure. Anterograde femoral intramedullary nailing can be performed in supine&#xD;
      position with a fracture table. Intraoperative sedation might be necessary for patients under&#xD;
      regional anesthesia on traction table. Dexmedetomidine is an alpha 2 receptor agonist that is&#xD;
      being used as an agent for its sedative and adjuvant analgesic effects.&#xD;
&#xD;
      The aim of this study is to evaluate the effects of dexmedetomidine premedication on&#xD;
      geriatric patients with end stage renal disease, who will be undergoing a surgical operation&#xD;
      for hip fracture under spinal anesthesia with hyperbaric bupivacaine and BIS (Bispectral&#xD;
      Index) guided sedation with intraoperative propofol infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into two separate groups.Group Dexmedetomidine (Group D):&#xD;
      Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal&#xD;
      block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30) Group Control (Group C): Midazolam 0.02&#xD;
      mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg)&#xD;
      (n=30)&#xD;
&#xD;
      In this randomized double-blinded study, drugs will be prepared by an anesthesia technician&#xD;
      who is not part of the study. The patients will be monitored with a pulse-oxymeter, 5-channel&#xD;
      ECG, noninvasive blood pressure and BIS at the preoperative preparation room. BIS monitoring&#xD;
      electrodes will be placed on the forehead of the patient. Study drugs will be administered to&#xD;
      the patient by another anesthesiologist who is also not taking part in the study at the&#xD;
      preparation room preoperatively. Dexmedetomidine (0.5 μg/kg) in 20 ml saline will be&#xD;
      administered in 10 minutes, with an infusion pump. An equivalent volume of saline solution&#xD;
      will be given to the control group with same method. Baseline, 1., 3., 5., 10., minute BIS&#xD;
      SpO2, systolic, diastolic and mean arteriel pressure values will be recorded. At this period&#xD;
      500 ml of 0.9% NaCl will be infused. The patient will then be transported to the operating&#xD;
      room with the supervision of this anesthesiologist. The intraoperative and postoperative&#xD;
      follow-up of the patients will be performed by another anesthesiologist who has been blinded&#xD;
      to the study drugs as well as the group distribution. Routine anesthesia monitoring will be&#xD;
      performed with pulse-oxymeter, 5-lead ECG, noninvasive blood pressure measurement, pulse&#xD;
      oxymetry and BIS. Before induction of the spinal block basal systolic, diastolic and mean&#xD;
      blood pressures, heart rate, peripheral oxygen saturation and BIS values will be recorded.&#xD;
      Lumbar puncture will be performed in lateral decubitis position with a Quincke 27 gauge&#xD;
      spinal needle at the L3-L4 interspaces using the midline approach. Patients will be promptly&#xD;
      rotated supine position after block induction. Induction of the spinal block will be accepted&#xD;
      as 0 for all intraoperative data recordings. Systolic, diastolic and mean blood pressures,&#xD;
      heart rate, peripheral oxygen saturation and BIS values will be recorded at 1.,3. 5. minutes&#xD;
      and every 5 minutes for the first hour and following that every 15 minutes during surgery.&#xD;
&#xD;
      Hypotension will be described as a drop off in systolic pressure by greater then 25% from the&#xD;
      baseline or in case systolic blood pressure decreases below 90 mm Hg, 5 mg ephedrine will be&#xD;
      administered intravenously and the rate of crystalloid infusion will be increased.&#xD;
&#xD;
      The sensorial block level and the motor block level will be tested with the pinprick test and&#xD;
      Bromage scale (Bromage Scale; 0: No motor block: full flexion of knee and foot, 1: Inability&#xD;
      to raise extended leg. Just able to move knee, 2: Inability to flex knee. Able to move foot&#xD;
      only, 3: Inability to flex ankle joint. Unable to move foot or knee), respectively. Propofol&#xD;
      infusion will be started in all patients at a dose of 50 mcg/kg/min after the level of block&#xD;
      arises to T10 dermatome level. Target BIS values will be between 70 and 80. Infusion rate&#xD;
      will be titrate to provide the targeted BIS levels.The time when BIS &lt; 80 will be recorded.&#xD;
      In case BIS&lt;70, propofol infusion rate will be reduced. ''Observer's assessment of&#xD;
      alertness/sedation (OAA/S)'' scale (OAAS score 5-awake and responds readily to name spoken in&#xD;
      normal tone, OAAS score 4-lethargic responses to name in normal tone, OAAS score 3-responds&#xD;
      only after name is called loudly and/or repeatedly, OAAS score 2-responds only after name&#xD;
      called loudly and mild shaking, OAAS score 1-does not respond when name is called loudly and&#xD;
      mild shaking or prodding, OAAS score 0-does not respond to noxious stimulation) will be used&#xD;
      for evaluating the level of sedation, with a target of OAA/S ≤ 5. OAA/S scores will be&#xD;
      registered at the same time points. Propofol infusion will be ended at the beginning of skin&#xD;
      suturing, and BIS&gt;90 time will be recorded.&#xD;
&#xD;
      Patients will be monitored at the postoperative care unit and all monitoring parameters (MAP,&#xD;
      SAP, DAP, BIS, OASS) will be registered at every 5 minutes for one hour. Criteria for&#xD;
      transferring the ward are BIS&gt;90, OAA/S=5, Bromage=0-1 Duration of the surgery, the amount of&#xD;
      bleeding, vasoactive drug need, the time necessary to reach the targeted level of sedation&#xD;
      (BIS≤80), the amount of propofol infusion, propofol dose required for targeted BIS levels and&#xD;
      the total propofol consumption recovery time (BIS&gt;90) first analgesic requirement time (VAS:&#xD;
      Visual Analogue Scale;0=no pain, 10=worst pain possible,VAS≥3) and the complications will be&#xD;
      recorded. Side effects and possible complications during the intraoperative period and the&#xD;
      postoperative follow-up include: hypotension (SBP&lt;90 mmHg), bradycardia (CR &lt; 60/min),&#xD;
      hypoxia (SpO2≤ 94 %), nausea, vomiting, and respiratory depression will be recorded and the&#xD;
      necessary medical interventions will be administered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease at the propofol doses and postoperative early recovery</measure>
    <time_frame>up to first 6 hours for postoperative pain management</time_frame>
    <description>In addition patients will be followed postoperatively first 6 hours for postoperative pain management at the ward.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Renal Failure</condition>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Group Dexmedetomidine (Group D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Control (Group C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine infusion for premedication</intervention_name>
    <description>Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)</description>
    <arm_group_label>Group Dexmedetomidine (Group D)</arm_group_label>
    <other_name>Precedex 200mcg/2ml</other_name>
    <other_name>121/87</other_name>
    <other_name>Hospira İnc., Rocky Mount, NC 27801 USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>intravenous Midazolam 0.02 mg/kg for premedication</description>
    <arm_group_label>Group Control (Group C)</arm_group_label>
    <arm_group_label>Group Dexmedetomidine (Group D)</arm_group_label>
    <other_name>Demizolam</other_name>
    <other_name>Dem İlaç San. ve Tic AŞ.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>Saline infusion to facilitate blinding</description>
    <arm_group_label>Group Control (Group C)</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg</intervention_name>
    <description>Hyperbaric bupivacaine injection for spinal block</description>
    <arm_group_label>Group Control (Group C)</arm_group_label>
    <arm_group_label>Group Dexmedetomidine (Group D)</arm_group_label>
    <other_name>Marcaine Spinal Heavy 0.5%</other_name>
    <other_name>Astra Zeneca</other_name>
    <other_name>21.01.2000-194/86</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elderly patients (above 65 years of age)&#xD;
&#xD;
          -  end stage renal failure on dialysis treatment (Glomerular filtration rate &lt;15, Stage&#xD;
             5)&#xD;
&#xD;
          -  hip fracture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with decompensated respiratory or heart failure,&#xD;
&#xD;
          -  liver failure&#xD;
&#xD;
          -  morbid obesity&#xD;
&#xD;
          -  mental disorders&#xD;
&#xD;
          -  cognitive disorders&#xD;
&#xD;
          -  language problems&#xD;
&#xD;
          -  patients with a contraindication for regional anesthesia (coagulopathy, history of&#xD;
             anticoagulant use, spinal cord disease and patients who rejected spinal anesthesia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anis Aribogan, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Baskent University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baskent University School of Medicine Adana Research and Teaching Center</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University School of Medicine Adana Teaching and Research Center</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent University School of Medicine Adana Teaching and Research Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ozkan-Seyhan T, Sungur MO, Senturk E, Karadeniz M, Basel A, Senturk M, Akpir K. BIS guided sedation with propofol during spinal anaesthesia: influence of anaesthetic level on sedation requirement. Br J Anaesth. 2006 May;96(5):645-9. Epub 2006 Mar 10.</citation>
    <PMID>16531442</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baskent University</investigator_affiliation>
    <investigator_full_name>Pinar Ergenoglu</investigator_full_name>
    <investigator_title>Specialist Doctor, Anesthesiology and Reanimation Department</investigator_title>
  </responsible_party>
  <keyword>Renal failure,</keyword>
  <keyword>hip fracture,</keyword>
  <keyword>spinal anesthesia,</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

